Evan David Seigerman
Stock Analyst at BMO Capital
(0.73)
# 1826
Out of 5,240 analysts
39
Total ratings
23.33%
Success rate
12.26%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Novo Nordisk | Maintains: Outperform | 156 105 | 83.78 | 25.33% | 5 | Dec 23, 2024 | |
Merck & Co | Downgrades: Market Perform | 136 105 | 100.32 | 4.67% | 3 | Dec 20, 2024 | |
Replimune Group | Maintains: Outperform | 14 18 | 10.83 | 66.2% | 2 | Nov 22, 2024 | |
AbbVie | Maintains: Outperform | 228 208 | 172.33 | 20.7% | 6 | Nov 12, 2024 | |
Regeneron Pharmaceut... | Maintains: Outperform | 1300 1190 | 698.75 | 70.3% | 5 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 52 57 | n/a | n/a | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 83 100 | 27.16 | 268.19% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 336 355 | 270.74 | 31.12% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 33 36 | 26.54 | 35.64% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 31 72 | n/a | n/a | 4 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 9 3 | 7.47 | -59.84% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 369 396 | 752.59 | -47.38% | 1 | Sep 6, 2022 |